Scienmag

FEBRUARY 10, 2021

Credit: Lei Dong, Nanjing University Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

In-Vivo 69

In-Vivo Scientist Engineer Medicine 69

Pharmaceutical Technology

SEPTEMBER 29, 2022

Under the agreement, Sanofi will receive non-exclusive rights to Scribe’s CRISPR by Design platform of wholly-owned enzymes for developing ex vivo NK cell therapies. The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer.

Development 130

Development In-Vivo Genome Genomics 130

Drug Discovery World

NOVEMBER 15, 2022

In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences, we use multiple sclerosis as a case-study of a neurodegenerative disease, so you can: Understand the key processes in neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration.

In-Vitro 52

In-Vitro In-Vivo Drugs Life Science 52

Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

Drug Discovery World

NOVEMBER 15, 2022

Discover how in vitro assays can be used to model in vivo neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration. Brought to you by DDW and Malvern Panalytical, the webinar is presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences. Watch the webinar now.

In-Vitro 52

In-Vitro Drugs In-Vivo Life Science 52

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

MAY 29, 2023

As a provider of AAV viral vectors, VectorBuilder has played a crucial role in freeing up our time to focus more on research by providing large quantities of high-quality viral vector for in vivo applications,” said Martin Madill, Senior Scientist at Purespring Therapeutics.

Gene Therapy 52

Gene Therapy In-Vivo Gene Sales 52

Scienmag

FEBRUARY 22, 2021

Using innovative in vivo imaging approaches, scientists […]. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” ” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. AdBio Partners’ mission is to support founding scientists in the development of new therapeutic approaches,” said Alain Huriez, Managing Partner of AdBio Partners.

Development 52

Development Life Science In-Vivo In-Vitro 52

Drug Discovery World

JANUARY 12, 2023

Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases.

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

APRIL 5, 2023

We will be collaborating closely with the consortium’s network of scientists to help fuel the world’s discovery engine in the fight against cancer.” Members contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and in vivo and in vitro models for oncology.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Best practice is to also consider the ‘developability’ of the lead compounds in conjunction with any evidence of potential in-vivo activity, by taking a holistic approach. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?

Development 130

Development In-Vivo Clinical Trials Clinical Trials 130

Drug Discovery World

NOVEMBER 9, 2023

Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’. Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

MARCH 4, 2024

By effectively running bioassays and analysing results, drug developers can efficiently optimise lead compounds, predict in vivo efficacy, and gain insights into the mechanism of action. RA: Does assay annotation remove some of the burden scientists face when performing/ analysing assays?

Drugs 59

Drugs Bioassay Scientist In-Vivo 59

Drug Discovery World

SEPTEMBER 21, 2022

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. Scientists also found in animal models that these unique cells slow and stop their own growth, keeping them in a dormant state in distant organs such as the lungs.

Regulation 52

Regulation Protein In-Vivo Scientist 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

Drug Discovery World

JANUARY 27, 2023

This comes just as Myosana has appointed its new CEO, Dr Matthew Lumley, a physician scientist who has spent nearly two decades in academic medicine and drug development. As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases.”

Gene Therapy 52

Gene Therapy Gene In-Vivo Development 52

Drug Discovery World

MARCH 15, 2024

Disease-modifying therapy for Parkinson’s The Nature Communications paper, published in November 2023 by scientists at Cambridge University, Harvard University and Mission Therapeutics, provided key experimental evidence to support the thesis that MTX325 can modify the course of Parkinson’s by targeting USP30.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vivo Trials 52

Drug Discovery World

MAY 9, 2023

The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted the inadequacy of animal models most often used for in vivo research. Cancer is far more complex than the sum of its parts. Mice have long been heroes of preclinical cancer research.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Drug Discovery World

APRIL 25, 2024

For drug discovery and development, cell lines allow researchers to test the efficacy of therapeutics before moving into in vivo studies. It is a crucial for the development of biopharmaceuticals since they use a living host to produce the therapeutic in question.

Development 59

Development Protein In-Vivo Life Science 59

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

Drug Discovery World

DECEMBER 13, 2023

Custom antibodies can be developed for pharmacokinetic assays and biodistribution assays, supporting therapeutic development by giving researchers data about the behaviour of their novel therapeutic in vivo. This article is sponsored by Fortis Life Sciences.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

pharmaphorum

AUGUST 5, 2021

The combination of MDC’s in vivo imaging and infrastructure, with WMIC’s heritage in radiochemistry, further strengthens the national PET Network, which has been established across the UK by MDC and leading academic centres of excellence. ” Find out more about MDCs PET Imaging expertise here.

Medicine 52

Medicine In-Vivo Packaging Packaging 52

Drug Discovery World

APRIL 12, 2023

Animal testing, whilst serving an important purpose for drug development has long been regarded as a contentious issue by both animal rights activists and scientists themselves. Animal models can be great indicators to assess how a drug will perform in vivo, in a particular species, but the human body is complex. This is essential.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

OCTOBER 2, 2023

DDW’s Megan Thomas heard from attendees about their key takeaways from the event. Dr Mindy Miller, Lead Research Scientist, Terumo Blood And Cell Technologies Conversations and data shared at the CAR-TCR 8 th Annual Summit highlighted the importance of optimising the science behind the therapies to broaden patient access.

In-Vivo 105

In-Vivo Manufacturing Production Gene Therapy 105

Drug Discovery World

NOVEMBER 7, 2023

DDW’s Megan Thomas looks at a day in the life of Richard Bouffard, Histology Director at Virscio. MT: Where do you work, and can you tell us what you’re working on at the moment? Common areas of research for us include wet and dry AMD, glaucoma, ischemic stroke, Parkinson’s, and Alzheimer’s, although the complete list is very broad.

Research 59

Research In-Vivo Gene Therapy Development 59

Drug Discovery World

JULY 5, 2023

A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

pharmaphorum

APRIL 6, 2021

Shiva Kazerounian , Associate Director & Principal Scientist – In Vivo Pharmacology, Berg Health. There is a crucial need to progress candidates from bench to bedside. With that in mind, I am delighted to share the official agenda and speaker faculty for the 9th PREDiCT: Tumor Models Cell Therapy Summit.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

The presentations are as follows: Fabian Schmich, PhD, Senior Data Scientist, pRED Informatics, Roche Diagnostics Deutschland, on: ‘scifAI: An explainable machine learning framework applied to functional characterisation of therapeutic antibodies’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

JANUARY 23, 2023

Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

NOVEMBER 8, 2023

Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’.

Antibody 64

Antibody Engineer Protein Scientist 64

Camargo

DECEMBER 22, 2021

For products that have an US RLD counterpart, FDA may waive in vivo study requirements, depending on the drug formulation, proposed indication, active ingredients, solubility, permeability, and other factors. However, they may generate undifferentiated labels that are not conducive to commercial success. Clinical Pharmacology.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

OCTOBER 3, 2022

As experimental data becomes bigger and more complex, scientists are challenged to make discoveries faster, consistently document and analyse their work, and easily collaborate across an organisation and with external partners. If an ELN is in the cloud, these benefits also come with no maintenance or upgrades required by the IT department.

Scientist 52

Scientist In-Vivo Drugs 52

Drug Discovery World

OCTOBER 27, 2023

With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72